Loading stock data…
$6.66-0.29 (-4.17%)
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Agenus Inc. in the Healthcare sector is trading at $6.84 with a market capitalization of $371M. Wall Street consensus targets $26.33 (3 analysts), implying a +284.7% move over the next 12 months. The stock is currently 34% below its 52-week high of $10.31, remaining 43.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.52M↑ | $33.74M↓ | $34.20M↑ | $30.23M↑ | $25.69M |
| Gross Profit | $19.76M↓ | $21.91M↓ | $26.69M↑ | $6.00M↑ | -$1.26M |
| Operating Income | $11.29M↓ | $15.05M↑ | $14.40M↑ | -$4.86M↑ | -$16.78M |
| Net Income | -$550,000↓ | $39.23M↑ | -$10.58M↓ | $63.91M↑ | -$27.95M |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identificati...